Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06247670
PHASE1

Study of CMP-CPS-001 in Healthy Volunteers

Sponsor: CAMP4 Therapeutics Corporation

View on ClinicalTrials.gov

Summary

The objective of this clinical study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of CMP-CPS-001 administered as a subcutaneous injection in adult healthy volunteers.

Official title: A Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study of CMP-CPS-001 in Healthy Volunteers

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

96

Start Date

2024-02-05

Completion Date

2025-08

Last Updated

2025-06-12

Healthy Volunteers

Yes

Interventions

DRUG

CMP-CPS-001

CMP-CPS-001 consists of an antisense oligonucleotide solution that will be administered subcutaneously.

OTHER

Placebo

Placebo is 0.9% normal saline solution and will be administered subcutaneously.

Locations (1)

Nucleus Network Brisbane (also known as Q-Pharm Pty Ltd)

Herston, Queensland, Australia